Haemoconcentration, renal function, and post-Discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: Insights fromthe everest trial

Stephen J. Greene, Mihai Gheorghiade*, Muthiah Vaduganathan, Andrew P. Ambrosy, Robert J. Mentz, Haris Subacius, Aldo P. Maggioni, Savina Nodari, Marvin A. Konstam, Javed Butler, Gerasimos Filippatos

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations


Aims Haemoconcentration has been studied as a marker of decongestion in patients with hospitalization for heart failure (HHF).We describe the relationship between haemoconcentration, worsening renal function, post-discharge outcomes, and clinical and laboratory markers of congestion in a large multinational cohort of patients with HHF. Methods and results In 1684 patients with HHF with ejection fraction (EF) ≤40% assigned to the placebo arm of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, absolute in-hospital haematocrit change was calculated as the change between baseline and discharge or day 7 (whichever occurred first). Patient characteristics, changes in renal function, and outcomes over a median follow-up of 9.9 months were compared by in-hospital haematocrit change. Overall, 26% of patients had evidence of haemoconcentration (i.e. ≥3% absolute increase in haematocrit). Patients with greater increases in haematocrit tended to have better baseline renal function. Haemoconcentration correlated with greater risk of in-hospital worsening renal function, but renal parameters generally returned to baseline within 4weeks post-discharge. Patients with haemoconcentrationwere less likely to have clinical congestion at discharge, and experienced greater in-hospital decreases in body weight and natriuretic peptide levels. After adjustment for baseline clinical risk factors, every 5% increase of in-hospital haematocrit changewas associated with a decreased risk of all-cause death [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.70-0.95]. Haematocrit change was also associated with decreased cardiovascular mortality or heart failure (HF) hospitalization at ≤100 days post-randomization (HR 0.73, 95% CI 0.71-0.76). Conclusion In this large cohort of patients with HHF with reduced EF, haemoconcentration was associated with greater improvements in congestion and decreased mortality and HF re-hospitalization despite an increased risk of in-hospital worsening renal function.

Original languageEnglish (US)
Pages (from-to)1401-1411
Number of pages11
JournalEuropean Journal of Heart Failure
Issue number12
StatePublished - Dec 2013


  • Congestion
  • Haematocrit
  • Haemoconcentration
  • Heart failure
  • Outcomes
  • Renal function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Haemoconcentration, renal function, and post-Discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: Insights fromthe everest trial'. Together they form a unique fingerprint.

Cite this